A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists

NCT06322641 — Completed, 300 participants, Novo Nordisk A/S

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

FLAME-ASCVD-Nephro A Multinational Survey-based Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists

Registry	NCT06322641
Status	Completed
Study type	Observational
Enrollment	300 (Actual)
Sponsor	Novo Nordisk A/S (Industry)
Conditions	Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD), Systemic Inflammation
Interventions	No treatment given (Other)
Dates	start 2024-03-26, primary completion 2024-05-10, completion 2024-05-10, first posted 2024-03-21, last updated 2024-07-26
Locations	1 site in United States

-Summary

The purpose of this survey is to collect information for scientific research and to better understand the role of systemic inflammation in identification, treatment and management of patients with Atherosclerotic Cardiovascular Disease (ASCVD) and Chronic Kidney Disease (CKD)

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
Nephrologist		Other: No treatment given	Nephrologist with ASCVD and CKD patients

No treatment given (Other): No treatment given

+Outcome measures

Primary outcomes

Nephrologists' perceptions towards the role of systemic inflammation in the identification, treatment and management of patients with ASCVD and CKD [At the time of survey response (Day 1)]: Multi-select from a defined list; Numerical; A 7-point Likert scale for measurement of agreement from 1 "strongly disagree" to 7 "strongly agree".

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
* Male or female, age above or equal to 18 years at the time of signing informed consent.
* Is a Nephrologist.
* Has been in practice greater than or equal to 3 years.
* Sees at least 20 patients with ASCVD and CKD per month.
* Treats patients for more than only dialysis

Exclusion Criteria:

* Previous participation in this study. Participation is defined as having given informed consent in this study
* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
* Does not meet inclusion criteria requirements

+Locations (1)

Facility	City	Country	Status
KJT Group, Inc.	Rochester, New York	United States

+Investigators

Clinical Transparency dept. 2834, Study director, Novo Nordisk A/S